TABLE 3.

Expected serologic response to treatment^a

Disease stage	Decrease in nontreponemal titer at:
	6 mo posttreatment	12 mo posttreatment	24 mo posttreatment
Primary	4-foldb	6-fold	8-fold
Secondary	6-fold	8-fold
Early latent		4-fold

^aAdapted from reference 191 with permission of the publisher. 

^bFor example, a fourfold decrease in titer is 1:32 to 1:8.